(S (NP (NNP Cytotoxic) (NN chemotherapy)) (VP (VBZ is) (NP (NP (DT a) (JJ common) (NN treatment)) (PP (IN for) (NP (JJ advanced) (NN prostate) (NN cancer))))) (. .))
(S (NP (DT These) (NNS tumors)) (VP (VBP are) (ADVP (RB also)) (VP (VBN known) (S (VP (TO to) (VP (VB rely) (PP (IN on) (NP (NP (NN angiogenesis)) (, ,) (NN i.e.) (, ,) (NP (NP (DT the) (NN growth)) (PP (IN of) (NP (JJ local) (NN microvasculature))) (PP (IN via) (NP (NP (NN chemical) (VBG signaling)) (VP (VBN produced) (PP (IN by) (NP (DT the) (NN tumor)))))))))))))) (. .))
(S (ADVP (RB Thus)) (, ,) (NP (JJ several) (JJ clinical) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBG investigating) (NP (NP (JJ antiangiogenic) (NN therapy)) (PP (IN for) (NP (JJ advanced) (NN prostate) (NN cancer))) (, ,) (PP (CC either) (PP (IN as) (NP (NN monotherapy))) (CC or) (VP (VBN combined) (PP (IN with) (NP (JJ standard) (NN cytotoxic) (NNS protocols))))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ complex) (JJ genetic) (NNS alterations)) (VP (VBG promoting) (NP (NN prostate) (NN cancer) (NN growth)))) (VP (VBP complicate) (NP (NP (DT the) (NN selection)) (PP (IN of) (NP (NP (DT the) (JJS best) (JJ chemotherapeutic) (NN approach)) (PP (IN for) (NP (NP (DT each) (NN patient) (POS 's)) (NN tumor))))))) (. .))
(S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP present) (NP (NP (DT a) (JJ mathematical) (NN model)) (PP (IN of) (NP (JJ prostate) (NN cancer) (NN growth) (CC and) (NN chemotherapy))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB enable) (S (NP (NNS physicians)) (VP (TO to) (VP (VB test) (CC and) (VB design) (NP (VBN personalized) (JJ chemotherapeutic) (NNS protocols)) (PP (IN in) (NP (NN silico)))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP use) (NP (DT the) (JJ phase-field) (NN method)) (S (VP (TO to) (VP (VB describe) (NP (NP (NN tumor) (NN growth)) (, ,) (SBAR (WHNP (WDT which)) (S (NP (PRP we)) (VP (VBP assume) (S (VP (TO to) (VP (VB be) (VP (VBN driven) (PP (IN by) (NP (DT a) (JJ generic) (NN nutrient))) (PP (VBG following) (NP (NN reaction-diffusion) (NNS dynamics))))))))))))))) (. .))
(S (NP (NP (NNP Tumor) (NN proliferation) (CC and) (NN apoptosis)) (PRN (-LRB- -LRB-) (FW i.e.) (, ,) (NP (VBD programmed) (NN cell) (NN death)) (-RRB- -RRB-))) (VP (MD can) (VP (VB be) (VP (VBN parameterized) (PP (IN with) (NP (JJ experimentally-determined) (NNS values)))))) (. .))
(S (NP (NNP Cytotoxic) (NN chemotherapy)) (VP (VBZ is) (VP (VBN included) (PP (IN as) (NP (NP (DT a) (NN term)) (VP (VBG downregulating) (NP (JJ tumor) (JJ net) (NN proliferation))))) (, ,) (SBAR (IN while) (S (NP (JJ antiangiogenic) (NN therapy)) (VP (VBZ is) (VP (VBN modeled) (PP (IN as) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (JJ intratumoral) (JJ nutrient) (NN supply))))))))))) (. .))
(S (NP (DT Another) (NN equation)) (VP (VBZ couples) (NP (DT the) (NN tumor) (NN phase) (NN field)) (PP (IN with) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (JJ prostate-specific) (NN antigen)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (DT an) (ADJP (RB extensively) (JJ used)) (NN prostate) (NN cancer) (NN biomarker)))))))))) (. .))
(S (S (NP (PRP We)) (VP (VBP prove) (NP (NP (DT the) (NN well-posedness)) (PP (IN of) (NP (PRP$ our) (NN model)))))) (CC and) (S (NP (PRP we)) (VP (VBP run) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (NP (JJ representative) (NNS simulations)) (VP (VBG using) (NP (DT an) (JJ isogeometric) (NN method)) (S (VP (TO to) (VP (VB explore) (NP (NP (JJ untreated) (NN tumor) (NN growth)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NP (NN cytotoxic) (NN chemotherapy)) (CC and) (NP (JJ antiangiogenic) (NN therapy))) (, ,) (UCP (DT both) (ADVP (RB alone)) (CC and) (VP (VBN combined)))))))))))))))) (. .))
(S (NP (PRP$ Our) (NNS simulations)) (VP (VBP show) (SBAR (IN that) (S (NP (PRP$ our) (NN model)) (VP (VBZ captures) (NP (NP (NP (DT the) (NN growth) (NNS morphologies)) (PP (IN of) (NP (NN prostate) (NN cancer)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ common) (NNS outcomes)) (PP (IN of) (NP (ADJP (NN cytotoxic) (CC and) (JJ antiangiogenic)) (UCP (NN mono) (CC and) (VBN combined)) (NN therapy))))))))) (. .))
(S (NP (PRP$ Our) (NN model)) (ADVP (RB also)) (VP (VBZ reproduces) (NP (NP (DT the) (JJ usual) (JJ temporal) (NNS trends)) (PP (IN in) (NP (NP (NN tumor) (NN volume)) (CC and) (NP (JJ prostate-specific) (NN antigen) (NN evolution)))) (VP (VBN observed) (PP (IN in) (NP (JJ previous) (NNS studies)))))) (. .))
